Synvista Therapeutics, Inc Report issue

For profit Phase 2 Phase 3
Founded: Montvale NJ United States (1986)
Status: Defunct (2014)

Organization Overview

First Clinical Trial
2001
NCT00045994
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

alagebrium (11 trials)

Drugs in Phase 2 Trials (2)

4,4-dimethyl-benziso-2h-selenazine (1 trial)

alt-2074 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 2)

Cardiovascular Diseases (Phase 3)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetic Nephropathies (Phase 2)

Dyspnea (Phase 2)

Heart Failure (Phase 2)

Heart Failure, Diastolic (Phase 2)

Hypertension (Phase 2)

Hypertrophy (Phase 2)

Hypertrophy, Left Ventricular (Phase 2)

Myocardial Ischemia (Phase 2)

Psoriasis (Phase 2)

Pulmonary Edema (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 3